
A ketamine troche is a flavored sublingual lozenge — typically 100–200 mg — that dissolves under the tongue for at-home treatment of depression, anxiety, and PTSD.
Troches are the format used in most at-home ketamine therapy programs because they combine the antidepressant effects of clinical ketamine with the convenience of taking medication at home.
A troche (rhymes with "broke-y") is a slow-dissolving lozenge designed to release medication through the mucous membranes of the mouth — either under the tongue (sublingual) or between the cheek and gum (buccal). Ketamine troches are compounded specifically for psychiatric use and contain a measured dose of ketamine, typically 100–200 mg, along with a flavor base.
Swallowing ketamine triggers significant first-pass liver metabolism, which destroys most of the dose before it reaches the brain. Sublingual absorption bypasses the liver and delivers a larger fraction of the dose directly into the bloodstream — about 25–30% bioavailability, versus roughly 10–20% if swallowed.
The trade-off vs. IV: lower bioavailability but no needles, no clinic visit, and substantially lower cost.
There are two timeframes patients care about — the session itself, and the antidepressant benefit afterward.
| Phase | Timing |
|---|---|
| Dissolution time | 10–15 min (held under tongue, not chewed or swallowed) |
| Onset of effects | 10–20 min after dosing begins |
| Peak | 30–60 min |
| Perceptible session effects | 1.5–3 hours |
| Antidepressant benefit | Days to weeks per session, often longer with maintenance dosing |
Factors that shift the timeline:
Ketamine troche dosing is highly individualized and set by the prescribing physician based on:
Typical starting doses are 100–150 mg, titrated based on response and tolerability. Some patients stabilize at lower doses; some require 200 mg or more. Self-adjusting the dose is unsafe — both higher (overdose, intense dissociation) and lower (sub-therapeutic) can lead to bad outcomes.
The three at-home and clinical formats compared:
| Feature | Troche (sublingual) | IV infusion | Nasal spray (Spravato) |
|---|---|---|---|
| Bioavailability | ~25–30% | 100% | ~50% |
| Onset | 10–20 min | Immediate | 5–10 min |
| Duration of session | 1.5–3 hr | 40 min in-clinic | 40 min in-clinic + 2 hr monitoring |
| Setting | At home, telehealth supervised | In-clinic | Certified Spravato clinic |
| Dose precision | Less precise (mucosal absorption varies) | Highly precise | Standardized 56/84 mg |
| Cost per session | Lowest | $400–800 | $600–900 |
| Insurance coverage | Rare | Rare | Common for TRD |
| Best for | Maintenance + new patients with mild-moderate symptoms | Initial response for severe cases | Patients whose TRD diagnosis unlocks coverage |
A common protocol: start with one or two in-clinic infusions to establish response, then transition to at-home troches for ongoing maintenance.
Patients typically report:
Most patients prefer a quiet, low-stimulation environment — eyes closed, headphones with calming music or a curated playlist, a supportive person available if needed. Many at-home programs provide structured guidance.
Post-session, the most common reports are improved mood, increased motivation, and a sense of relief from depressive "heaviness." These effects can build over a course of treatment.
Common and short-lived:
Less common:
These typically resolve within hours. Patients should not drive or operate machinery for at least 4–6 hours after a session.
When prescribed by a licensed physician and used within a structured protocol, ketamine troches have a favorable safety profile. The risks come from misuse:
A physician-led program handles all of these — initial assessment, dose titration, ongoing monitoring, and adjustment.
Place the troche under the tongue or between the cheek and gum. Let it dissolve over 10–15 minutes without chewing or swallowing prematurely. Your provider will give specific instructions on whether to spit or swallow the remaining saliva — this affects the dose absorbed. Remain seated or lying down in a comfortable, low-stimulation environment during and after dissolution.
Swallowing the dissolved material isn't harmful but reduces effective dose substantially — first-pass liver metabolism breaks down most swallowed ketamine. The sublingual or buccal route is preferred. Follow your provider's specific instructions.
Yes — ketamine HCl troches are sometimes prescribed off-label for certain types of chronic pain, particularly neuropathic pain, because ketamine modulates pain signal transmission via NMDA receptor blockade. The protocol is different from psychiatric use; talk to a pain specialist.
By the prescribing physician, based on weight, diagnosis, prior ketamine response, and concurrent medications. Typical starting doses are 100–150 mg, titrated over the first few sessions. Self-adjusting is unsafe.
Protocols vary widely. Common patterns: an initial induction series (e.g., 2 sessions per week for 3 weeks) followed by maintenance (every 1–4 weeks). Some patients respond well to a more sparse schedule once stable. Your provider sets the cadence based on response.
Rarely, because they are compounded and used off-label. Most patients pay out of pocket, though many providers accept HSA/FSA. See pricing for current cost.
Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.
88.8% of Isha Health patients with moderate-to-severe depression show measurable improvement
Based on 546 patients and 1,900+ validated assessments. See our clinical outcomes →
Stay informed on ketamine therapy
Research updates, clinical insights, and mental health resources — delivered to your inbox.